STOCK TITAN
  1. Home
  2. Sec-filings
  3. BOLT
  4. [Form 4] Bolt Biotherapeutics, Inc. Insider Trading Activity

Bolt Biotherapeutics (BOLT) director files insider option changes on Form 4

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

A director of Bolt Biotherapeutics, Inc. reported cancelling previously granted director stock options and receiving new options with lower exercise prices.

On December 12, 2025, the director received new options to buy 2,500, 849, 1,000 and 1,100 shares of common stock at an exercise price of $5.44 per share, with expiration dates between September 2, 2034 and May 26, 2035. In each case, options with higher exercise prices ranging from $6.40 to $13.596 for the same number of shares and similar expiration dates were cancelled in exchange for the new options, some of which are fully vested and others subject to monthly or time-based vesting and full vesting upon a change in control.

Positive

  • None.

Negative

  • None.
Insider Dupont Jakob
Role Director
Type Security Shares Price Value
Grant/Award Director Stock Option (Right to Buy) 2,500 $0.00 --
Disposition Director Stock Option (Right to Buy) 2,500 $0.00 --
Grant/Award Director Stock Option (Right to Buy) 849 $0.00 --
Disposition Director Stock Option (Right to Buy) 849 $0.00 --
Grant/Award Director Stock Option (Right to Buy) 1,000 $0.00 --
Disposition Director Stock Option (Right to Buy) 1,000 $0.00 --
Grant/Award Director Stock Option (Right to Buy) 1,100 $0.00 --
Disposition Director Stock Option (Right to Buy) 1,100 $0.00 --
Holdings After Transaction: Director Stock Option (Right to Buy) — 2,500 shares (Direct)
Footnotes (1)
  1. For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the shares will vest upon the Reporting Person completing each month of continuous service following September 3, 2024; provided, however that the option will vest in full upon a change in control. The reporting person agreed to cancellation of an option granted on September 3, 2024, in exchange for a new option having a lower exercise price. The option is fully vested and exercisable. The reporting person agreed to cancellation of an option granted on September 3, 2024, in exchange for a new option having a lower exercise price. The reporting person agreed to cancellation of an option granted on May 1, 2025, in exchange for a new option having a lower exercise price. The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dupont Jakob
(Last) (First) (Middle)
C/O BOLT BIOTHERAPEUTICS, INC.
900 CHESAPEAKE DRIVE
(Street)
REDWOOD CITY CA 94063
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Bolt Biotherapeutics, Inc. [ BOLT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Director Stock Option (Right to Buy) $5.44 12/12/2025 A 2,500 (1) 09/02/2034 Common Stock 2,500 (2) 2,500 D
Director Stock Option (Right to Buy) $13.596 12/12/2025 D 2,500 (1) 09/02/2034 Common Stock 2,500 (2) 0 D
Director Stock Option (Right to Buy) $5.44 12/12/2025 A 849 (3) 09/02/2034 Common Stock 849 (4) 849 D
Director Stock Option (Right to Buy) $13.596 12/12/2025 D 849 (3) 09/02/2034 Common Stock 849 (4) 0 D
Director Stock Option (Right to Buy) $5.44 12/12/2025 A 1,000 (3) 04/30/2035 Common Stock 1,000 (5) 1,000 D
Director Stock Option (Right to Buy) $7.02 12/12/2025 D 1,000 (3) 04/30/2035 Common Stock 1,000 (5) 0 D
Director Stock Option (Right to Buy) $5.44 12/12/2025 A 1,100 (6) 05/26/2035 Common Stock 1,100 (7) 1,100 D
Director Stock Option (Right to Buy) $6.4 12/12/2025 D 1,100 (6) 05/26/2035 Common Stock 1,100 (7) 0 D
Explanation of Responses:
1. For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the shares will vest upon the Reporting Person completing each month of continuous service following September 3, 2024; provided, however that the option will vest in full upon a change in control.
2. The reporting person agreed to cancellation of an option granted on September 3, 2024, in exchange for a new option having a lower exercise price.
3. The option is fully vested and exercisable.
4. The reporting person agreed to cancellation of an option granted on September 3, 2024, in exchange for a new option having a lower exercise price.
5. The reporting person agreed to cancellation of an option granted on May 1, 2025, in exchange for a new option having a lower exercise price.
6. The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.
7. The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price.
/s/ William P. Quinn, Attorney-in-Fact 12/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Bolt Biotherapeutics (BOLT) disclose in this Form 4?

A Bolt Biotherapeutics director reported cancelling several existing director stock options with higher exercise prices and receiving new stock options with a lower exercise price of $5.44 per share on December 12, 2025.

Which Bolt Biotherapeutics (BOLT) stock options were repriced and what were the exercise prices?

The director received new options at an exercise price of $5.44 per share covering blocks of 2,500, 849, 1,000 and 1,100 shares of common stock. In exchange, options on the same numbers of shares with higher exercise prices of $13.596, $7.02 and $6.40 were cancelled.

What are the expiration dates and vesting terms of the new Bolt Biotherapeutics (BOLT) options?

The new options expire on September 2, 2034, April 30, 2035 and May 26, 2035, depending on the grant. One grant vests in monthly installments starting after September 3, 2024 with full vesting upon a change in control, others are fully vested, and one vests on the earlier of May 27, 2026 or the day immediately prior to the next annual stockholder meeting, with full vesting upon a change in control.

What is the reporting person’s relationship to Bolt Biotherapeutics (BOLT)?

The reporting person is identified as a Director of Bolt Biotherapeutics, Inc., and the filing is indicated as a Form filed by one reporting person.

Who signed the Bolt Biotherapeutics (BOLT) Form 4 relating to these option changes?

The Form 4 was signed by /s/ William P. Quinn, Attorney-in-Fact, on December 16, 2025, acting on behalf of the reporting person.

Do any of the new Bolt Biotherapeutics (BOLT) options vest upon a change in control?

Yes. One option grant provides that all remaining shares will vest in full upon a change in control, and another provides for full vesting upon a change in control of the issuer in addition to its time-based vesting schedule.